Enhanced yield and cannabinoid production of homogenous medical marijuana plants

该提案中的这项研究表明，将产生与迅速发展的大麻产业相关的关键知识，以提供具有一致大麻素浓度的高质量植物材料。该项目将解决三个知识空白：1)基于遗传和代谢组学标记，为质量控制目的快速鉴定大麻品种；2)稳定广受欢迎的大麻品种的遗传，并开发通过种子繁殖这些品系的方法；3)利用微生物信号化合物改变产量、大麻素浓度和植物抗病性。这项研究很重要，因为大麻生产商必须能够种植一致的医用植物材料，以便在将大麻类药物作为药用药物处方时提供可靠的剂量(数量和成分)。此外，必须解决植物对白粉病的抗病问题，因为目前注册的控制产品很少，导致产量和质量大幅下降；本研究项目中建议的方法也不会在将用于人类消费的花卉上留下化学痕迹。这项研究对1)大麻生产商、2)临床医生和3)患者都很重要。大麻生产商将受益于产量损失的减少；临床医生将受益于更广泛的一致性大麻产品，这些产品可以在治疗各种医疗疾病的临床试验中进行评估；患者将受益于获得一系列高质量大麻药物的机会。该项目的预期成果是1)基于遗传和代谢物的快速和廉价的大麻品系鉴定系统，2)生产遗传相同的雌性大麻种子的方法，以及3)调节大麻素浓度和成分以及控制大麻白粉病的新策略。工业合作伙伴RavenQuest Bimed将从改进的生产方法和一致的、具有良好特性的植物遗传学中受益。加拿大将受益于利用这一知识将自己定位为高质量医用大麻生产的世界领先者，从而增加大麻销售的税收。

This research indicated in this proposal will produce critical knowledge relevant for the rapidly-expanding Cannabis industry, to provide high quality plant material with consistent cannabinoid concentrations. The project will address three knowledge gaps: 1) identifying Cannabis cultivars quickly, based on genetic and metabolomics markers, for quality control purposes; 2) stabilizing genetics of popular Cannabis cultivars and developing methods for propagating these lines via seeds; 3) altering yield, cannabinoid concentration and plant disease resistance using a microbial signal compound. This research is important because Cannabis producers must be able to grow consistent plant material for medical use in order to provide reliable doses (amount and composition) of cannabinoids when it is prescribed as a pharmaceutical-grade drug. Furthermore, plant disease resistance against powdery mildew must be addressed, since currently few registered control products are available, resulting in significant yield and quality reductions; the proposed method in this research project would also not leave chemical traces on flowers that will be used for human consumption. This research is important to 1) Cannabis producers, 2) clinicians and 3) patients. Cannabis producers will benefit from reduced yield losses; clinicians will benefit from a wider range of consistent Cannabis products that can be evaluated in clinical trials for treatment of a variety of medical conditions; patients will benefit from improved access to a range of high-quality Cannabis-based pharmaceutical products. The anticipated outcomes of this project are 1) a rapid and inexpensive identification system for Cannabis strains based on genetics and metabolites, 2) a method for producing genetically identical female Cannabis seeds, and 3) a novel strategy for regulating cannabinoid concentrations and composition and powdery mildew control in Cannabis. RavenQuest Biomed, the industrial partner, will benefit through improved production methods and consistent and well characterized plant genetics. Canada will benefit by using this knowledge to position itself as a world leader in production of high-quality medical Cannabis, increased tax revenues from Cannabis sales.